111 results about "Celiac diseases" patented technology

The invention discloses kluyveromyces marxianus KUST3801 for preventing and treating celiac disease, application of the kluyveromyces marxianus KUST3801 and a fruit and vegetable fermented beverage. The preservation number is CGMCC NO. 32767; the Kluyveromyces marxianus strain is classified and named as Kluyveromyces marxianus, and the Kluyveromyces marxianus strain is named as Kluyveromyces marxianus. The strain can be used for effectively preventing and treating celiac disease by protecting intestinal mucosa and intestinal barrier, regulating immunity and relieving inflammation. In addition, in the preparation of the fermented fruit and vegetable juice beverage, the aroma of the beverage can be improved, and the antioxidant activity is enhanced.

A monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. A nucleic acid encoding the antibody or antigen-binding fragment thereof, an expression vector, a method for preparing the antibody, and use of the antibody in treatment of diseases or disorders associated with the human T cell receptor family. The generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

The present invention relates to monoclonal humanized antibodies or antigen-binding fragments thereof that specifically bind to the TRBV9 family of human T-cell receptors. The present invention also relates to nucleic acids encoding said antibodies or antigen-binding fragments thereof, expression vectors, methods for preparing said antibodies and the use of said antibodies in the treatment of diseases or disorders associated with said family of human T-cell receptors. The present invention relates to the production of antibodies that can be used to treat, inter alia, ankylosing spondylitis (AS or Bechterev's disease), celiac disease and blood cancers, whose pathogenesis involves T-cell receptors of the TRBV9 family.

The present disclosure relates to novel deuterated analogs of the sirtuin 6 (SIRT6) modulator IMU-856, pharmaceutical formulations comprising them, a process for their preparation and their use as medicament, alone or in combination with one or more additional agents, for preventing and / or treating of various diseases, wherein the modulation of SIRT6 is desirable, e.g. in celiac disease.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

The invention relates to gluten-free premixed flour for steamed rice cakes and application of the gluten-free premixed flour in preparation of the steamed rice cakes. The gluten-free rice steamed cake premixed flour comprises the following components in percentage by mass: 81%-90% of compound rice flour, 8%-13% of milk powder and 2%-6% of a compound modifier. The gluten-free pure rice steamed cake is prepared by using the gluten-free rice steamed cake premixed flour, and the gluten-free pure rice steamed cake is prepared by using indica rice flour as a main raw material, and is easy to form, good in taste, and good in water-retaining property and texture state. And as a gluten-free product, the food meets the requirements of celiac disease patients on balanced nutrition diet. And the problems that the steamed cake is dry in taste, heavy in granular sensation and not fine and smooth due to the fact that water is easy to lose in a short-term preservation period are also solved. Meanwhile, the rice cake prepared from the gluten-free steamed cake premixed flour is simple, convenient and healthy.

Disclosed herein are formulations, substrates, and arrays. Also disclosed herein are methods for manufacturing and using the formulations, substrates, and arrays. Also disclosed are methods for identifying peptide sequences useful for diagnosis and treatment of disorders, and methods for using the peptide sequences for diagnosis and treatment of disorders, e.g., celiac disorder. In certain embodiments, substrates and arrays comprise a porous layer for synthesis and attachment of polymers or biomolecules.

The present disclosure is directed to novel method and formulation for producing egg free and gluten-free bread with a dough system providing an improved texture (softness, chewiness, moisture), shape (large baguette), appearance and taste, used for garlic toast and other applications. The formulation includes a combination of gluten-free flours (tapioca starch-modified, corn starch, potato starch, rice flour), leavening agent, binding agents (hemp heart protein and hydroxypropyl-methylcellulose HPMC), and additives to achieve a desired bread product suitable for individuals with gluten intolerance or celiac disease. The method involves specific steps to mix, proof, shape, and bake the dough to ensure optimal quality and consistency of bread slices used for garlic toast application and other bakery products.

The present disclosure provides Multimeric Antigen-Presenting Polypeptides (MAPPs) for the presentation of epitopes in the context of a class II MHC receptor. The present disclosure provides nucleic acids comprising nucleotide sequences encoding those MAPPs, as well as cells genetically modified with the nucleic acids encoding the MAPPs. MAPPs are useful for selectively modulating activity of T cells having T cell receptors that recognize the antigens. Thus, the present disclosure provides compositions and methods for modulating the activity of T cells, as well as compositions and methods for treating persons who have diseases and / or disorders including metabolic disorders, cancers, autoimmune diseases, allergies, T1D, and / or celiac disease.

A Bifidobacterium longum subsp longum produced by a method of growing the Bifidobacterium longum subsp longum in a culture medium, the culture medium containing a fructose disaccharide, FOS or combination thereof. A method for treatment or prevention of inflammatory bowel disease, celiac disease, non-celiac gluten sensitivity, gluten ataxia, dermatitis herpetiformis or wheat allergy in an individual, the method including administering a combination of (i) Bifidobacterium longum subsp longum and (ii) a fructose disaccharide, FOS or a combination thereof to the individual.

Interleukin-23 receptor (IL23R) VHH antibodies are disclosed, as well as methods of making and using the same, e.g., for treatment of IL23-mediated diseases and disorders, including, e.g., gastrointestinal-related (Gl-related) diseases (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn's disease (CD)), a colon cancer, a small intestine cancer, a gastric cancer, an irritable bowel syndrome, a gastrointestinal ulcer, a gut-associated infection (e.g., a Salmonella infection or a Clostridium difficile infection), celiac disease, or pathogenic inflammation).

The present invention relates to a pharmaceutical combination comprising a first active ingredient, which is a CXCR3 antagonist 1-{(R)-2-(2-hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl}-2-(3-methyl-[1, 2, 4] triazole-5-yl)-2-(3-methyl-[1, 2, 3] triazole-5-yl)-2-(3-methyl-[1, 2, 3] triazole-5-yl)-2-(3-methyl-[1, 2, 3] a second active ingredient (which is an anti-CD3 monoclonal antibody (mAb)) and a second active ingredient (which is an anti-CD3 monoclonal antibody (mAb)); the invention also relates to the application of the medicine combination in the prevention / prevention and / or treatment of (autoimmune) / inflammation-mediated conditions (including type 1 diabetes mellitus (T1D) (especially autoimmune T1D), multiple sclerosis, organ transplant rejection (especially kidney and heart allograft rejection), thyroid eye diseases, rheumatoid arthritis, ulcerative colitis, Crohn's disease, celiac disease, and the like), and also relates to the application of the medicine combination in the prevention / prevention and / or treatment of (autoimmune) / inflammation-mediated conditions (including type 1 diabetes mellitus (T1D) (especially autoimmune T1D), multiple sclerosis, organ transplant rejection (especially kidney and heart allograft rejection), thyroid eye diseases, rheumatoid arthritis, ulcerative colitis, Crohn's disease, celiac disease and the like. The traditional Chinese medicine composition can be used for treating psoriasis, atherosclerosis, psoriasis, lung inflammation and psoriatic arthritis

The compositions and methods provided herein are related, in part, to the discovery of cholic acid 7-sulfate as a treatment for diabetes. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVII).

The invention relates to cell-assembled matrices, which resemble the endomysium and which are not taken from animal or human tissue, and which comprise antigen for celiac disease-specific antibodies; as well as solid phase matrix preparations comprising said cell-assembled matrices. Furthermore, methods for producing the cell-assembled matrix or the solid phase matrix preparation comprising the cell-assembled matrix are also disclosed. In addition, uses of the cell-assembled matrix or the solid phase matrix preparation comprising the cell-assembled matrix in a method for detecting celiac disease-specific antibodies in a sample or in a method for the in vitro diagnosis or evaluation of celiac disease in a subject are also disclosed.

The invention discloses a phosphatidylserine modified gliadin nanoparticle as well as a preparation method and application thereof. The phosphatidylserine modified gliadin nanoparticle is of a core-shell structure, gliadin is entrapped by polylactic acid-glycolic acid copolymer to serve as a core, and a lipid composite membrane formed by phosphatidylserine and DSPE-PEG2000 is coated outside the nanoparticle. The gliadin-loaded nanoparticles modified by phosphatidylserine are used for simulating membrane signal characteristics of apoptotic bodies, enhancing recognition and uptake of the nanoparticles by macrophages and inducing tolerance phenotypic transformation of the nanoparticles, so that immune tolerance of celiac disease patients to gliadin is recovered, and the gliadin-loaded nanoparticles can be used for treating celiac disease patients. On the basis of simplifying the preparation process, the problems of unstable tolerance effect and lack of metabolic regulation in the existing nano immunotherapy are further solved. The nano-particles prepared by the technical route have good particle size distribution and stability, can effectively deliver antigens and induce immune tolerance, and are a novel convertible celiac disease treatment nano-preparation.

Methods enabling prediction, screening, early diagnosis, and recommended intervention or treatment selection of autoimmune conditions using artificial intelligence operating in conjunction with large medical datasets. Logic is applied to historic population data to extract medical features and identify subjects with diagnosed autoimmune conditions, and the pre-diagnosis medical data is used to train a diagnosis classification algorithm. A self-supervised learning mechanism is separately used to generate a feature embedding transformation of the patients medical history into representational feature vectors. These patient feature vectors together with their expected diagnoses are used to train a multi-label classifier model using supervised learning. The embedding transformation and the multi-label classifier are then applied to a current subjects data to generate a patient diagnosis probability vector, predicting the existence of autoimmune conditions. These methods are applied to diagnose gastrointestinal autoimmune disorders using celiac disease as example.

The present disclosure is directed to novel method and formulation for producing egg free and gluten-free bread with a dough system providing an improved texture (softness, chewiness, moisture), shape (large baguette), appearance and taste, used for garlic toast and other applications. The formulation includes a combination of gluten-free flours (tapioca starch-modified, corn starch, potato starch, rice flour), leavening agent, binding agents (hemp heart protein and hydroxypropyl-methylcellulose HPMC), and additives to achieve a desired bread product suitable for individuals with gluten intolerance or celiac disease. The method involves specific steps to mix, proof, shape, and bake the dough to ensure optimal quality and consistency of bread slices used for garlic toast application and other bakery products.

Described herein are methods and compositions relating to inhibition of bile salt hydrolase (BSH) and uses thereof. Provided herein are methods for treating metabolic disorders (e.g., diabetes, obesity), gastrointestinal diseases (e.g., gastrointestinal infections; inflammatory bowel disease (IBD); appendicitis; crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; a liver disease (e.g., non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis), gastroesophageal reflux disease (GERD); celiac disease; diverticulosis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; intestinal leakage; the present invention relates to a method for treating a cancer (e.g., digestive cancer, liver cancer), a cancer (e.g., digestive cancer, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis). The method comprises administering to the subject a compound of Formula (I)-(XVIII).

Described herein are methods and compositions related to inhibiting bile salt hydrolase (BSH) and uses thereof. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), gastrointestinal disease (e.g., a gastrointestinal infection; inflammatory bowel disease (IBD); appendicitis; Crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; liver diseases (e.g., Non-alcoholic Fatty Liver Disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis of the liver) gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; leaky gut; and cancer), cancer (e.g., cancer of the digestive system, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVIII).

Described herein are methods and compositions relating to the inhibition of bile salt hydrolase (BSH) and uses thereof.SOLUTION: Provided herein are methods for treating metabolic disorders (e.g., diabetes, obesity), gastrointestinal diseases (such as gastrointestinal infections; inflammatory bowel diseases (IBD); appendicitis; Crohn's disease (CD); ulcerative cholitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetics; hepatits; hepatic diseases (such as non-alcoholic fatty liver disease (NAFLD); non-alcoholic fat hepatits (NASH); hepatits A; hepatits B; hepatits C; autoimmune hepatits; and cirrhosis of the liver); gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcers; infectious colitis; irritable bowel syndromes; intestinal wall leakage; and cancers); Methods for treating cancer (e.g., cancer of the digestive system, liver cancer) or inflammatory diseases (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcers, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to the subject a compound represented by Formulae (I) - (XVIII).SELECTED DRAWING: None

The present invention relates to a method for selecting or adjusting a therapy regimen for a subject having been diagnosed with celiac disease, wherein the therapy regimen comprises at least the treatment of celiac disease by administering a therapeutically effective amount of at least one transglutaminase 2 (TG2) inhibitor to said subject, wherein selecting or adjusting the therapy regimen is based on human leukocyte antigen DQ haplotypes of said subject.

The invention is a medical measurement system for measuring gluten levels in the blood. The system consists of an electronic circuit that reads the test values and a strip sensor based on gluten-sensitive nanoflower electroactive material that can be integrated into the electronic circuit and provides ease of individual use with practical and low-cost measurements. This measurement system enables people with conditions such as celiac disease and gluten intolerance to monitor gluten daily.

Disclosed are MHC Class II constructs (CIICs) comprising DQ and DR gene products that can present peptide epitopes associated with cancers, allergies, autoimmune diseases (e.g., T1D and celiac disease), GVHD, HGVD, and infections to T cell receptors. The CIICs may also comprise sequences of immunomodulatory molecules (MODs) such as IL-2 or PD-L1 that can modulate receptors on the surface of T cells. CIICs are expressible at levels up to about 350 mg / I in culture, and are substantially stable to multiple freeze thaw cycles and to thermal denaturation at 42° C. The stability of CIICs and their ability to present peptide epitopes and MODs to T cells and their renders them useful as therapeutics for in vitro and in vivo methods of treating various cancers, allergies, autoimmune diseases (e.g., T1D and celiac disease), GVHD, HGVD, and infections.

An aspartic protease and the use of the aspartic protease in the hydrolysis of gluten. This protease can hydrolyze gluten and the gluten-derived immunogenic peptides at pH 2.0˜4.0. Also provided are methods for the production of the aspartic protease, including recombinant plasmids, transformants, and a purification method thereof; methods of using the aspartic protease to prepare drugs and oral enzyme supplements for treatment of diseases or discomforts related to gluten ingestion, such as celiac disease; and a method of using the asparic protease in food-processing process to remove or reduce gluten in foods or beverages.

The present disclosure relates to methods for expressing recombinant nepocin polypeptides, host cells and expression vectors for expressing recombinant nepocin polypeptides, and methods of using the expressed nepocin polypeptides for therapeutic and other purposes. The present disclosure provides, in particular, methods for expressing recombinant nepocin polypeptides that result in efficient expression of soluble forms of nepocin, and the use of recombinant nepocin polypeptides in the treatment of diseases or conditions associated with gluten intolerance such as celiac disease.

User interface with imaging biomarkers for celiac disease treatment

The invention discloses a preparation method of gluten-free mung bean noodles. The preparation method comprises the following steps: 1) screening high-quality mung beans; (2) soaking the cleaned mung beans in a CaCl2 solution; (3) peeling the soaked mung beans; (4) drying the mung bean hulls and the peeled mung beans; 5) preparing mung bean powder and mung bean hull powder; (6) adding potato starch, enzyme, salt and water into the mung bean powder and the mung bean hull powder; and 7) applying simple shear flow and heating to the fermented dough by using a Couette cell device to obtain the gluten-free mung bean noodles capable of relieving summer-heat. The preparation method of the gluten-free mung bean noodles is simple and convenient, few ingredients are added, the gluten-free mung bean noodles are rich in protein and suitable for industrial production, the gluten-free mung bean noodles are not only suitable for celiac disease patients, but also vitexin contained in mung beans has the effects of clearing away heat and toxic materials, the defect that mixed beans are poor in processing suitability is overcome, and the gluten-free mung bean noodles are suitable for the celiac disease patients. The prepared noodles are rich in nutrition and chewy and smooth in mouth feel.

To provide dipeptidyl peptidase IV (DPPIV) that retains activity and is resistant to at least partial degradation.SOLUTION: Disclosed is a polypeptide comprising a terminal truncated dipeptidyl peptidase IV (DPPIV) polypeptide. The polypeptide is useful in medical applications such as in the treatment of gluten-related disorders including celiac disease (CeD) and non-celiac gluten sensitivity (NCGS) as well as other diseases that may benefit from a gluten-free diet (GFD).SELECTED DRAWING: None